HKSH’s First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate Minimises Cardiopulmonary Concerns and Maintains Quality of Life

(7 July 2026, Hong Kong) The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including breast, prostate as well as head and neck cancers, and has since accumulated about 940 cases of clinical data. Around 45% of its proton therapy treatments involve breast cancer patients receiving postoperative radiotherapy to reduce the risk of recurrence. Leveraging its clinical experience and innovative technologies in breast cancer proton therapy, HKSH has presented two clinical studies focusing on Chinese breast cancer patients at the Asia-Oceania Particle Therapy Co-operative Group 2025 (PTCOG-AO) and Particle Therapy Co-operative Group Annual Conference 2026 (PTCOG). Both studies are the first of their kind in Asia and further advance precision medicine aimed at helping patients “live with cancer while preserving quality of life.”